Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Japanese CRO Support Firm SRD Acquires Expartner Japan

This article was originally published in PharmAsia News

Executive Summary

Tokyo-based Japanese contract research organization support company SRD acquires Expartner Japan, a Tokyo-based consulting company for outsourcing medical devices and related regulatory affairs. SRD has acquired 80 percent of EPJ shares. Through the acquisition, SRD hopes to develop a synergy by combining EPJ's expertise in medical devices, related regulatory affairs and approval application support, with its own business in CRO and site management organization support, as well as good laboratory practices testing facilities. According to SRD, the company hopes the synergy will bear fruit to a whole process support system to serve both domestic and overseas medical device makers. Along with a strengthened device support business, SRD also plans to enter the regenerative medicine support business area. (Click here for more - Japanese language

You may also be interested in...

FDA Approves Medtronic’s Abre Venous Stent

The approval is based on the results ABRE clinical study, which showed the stent improved patency iliofemoral veins in 88% of cases with a 2% rate of major adverse events.

AbbVie Investors Look For Stabilizing Botox Revenues In Q3 Financials

Reporting its first full quarter of financials since merging with Allergan, AbbVie will be scrutinized for whether its optimistic talk of a quick Botox rebound actually happened.

COVID-19 Could Drive UK OTC Rises

Generic OTC paracetamol and ibuprofen pack prices are gradually returning to pre-COVID levels, according to market analysts Wavedata. But a second wave could drive prices back up again.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts